Keratoconus progression is not inhibited by reducing eyelid muscular force with botulinum toxin A treatment: a randomized trial
Conclusion: BTX-A inhibition of eyelid force generation did not result in detectable changes in corneal parameters in keratoconic patients during 18 months of follow-up.RESUMO Objetivo: Avaliar se a administra ção da toxina botulínica tipo A (BTX-A) no músculo orbicular de pacientes com ceratocone a fim de reduzir a força muscular palpebral pode alterar os parâmetros corneanos indicativos de progressão da doença. Métodos: Ensaio clínico randomizado paralelo prospectivo. Quarenta olhos de 40 pac ientes, randomizados em grupo controle ou grupo BTX-A na raz&...
Source: Arquivos Brasileiros de Oftalmologia - June 6, 2017 Category: Opthalmology Source Type: research

An objective assessment of Botulinum toxin type A injection in the treatment of post facial palsy synkinesis and hyperkinesis using the Synkinesis Assessment Questionnaire (SAQ)
The aim of this study is to provide reliable and valid evidence that Botulinum toxin (BTX-A) is a successful treatment for facial synkinesis in facial palsy using the synkinesis assessment questionnaire tool (SAQ). 51 patients completed questionnaires pre and post BTX-A treatment over 103 cycles of treatment. Each patient was individually assessed and then treated according to their presenting symptoms with a dosage in each injection site of between 0.5 to 5 U of BTX-A. A two-tailed, paired samples t-test was used to compare the scores for each question before and after treatment. (Source: Journal of Plastic, Reconstructiv...
Source: Journal of Plastic, Reconstructive and Aesthetic Surgery - June 2, 2017 Category: Cosmetic Surgery Authors: Catriona Neville, Vanessa Venables, Margaret Aslet, Charles Nduka, Ruben Kannan Source Type: research

An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire
This study aimed to provide reliable and valid evidence that botulinum toxin type A (BTX-A) is a successful treatment for facial synkinesis in facial palsy by using the synkinesis assessment questionnaire (SAQ) tool. Fifty-one patients completed questionnaires pre- and post-BTX-A treatment over 103 cycles of treatment. Each patient was individually assessed and then treated according to their presenting symptoms with a dosage in each injection site of between 0.5 and 5  U of BTX-A. A two-tailed paired samples t-test was used to compare the scores for each question before and after treatment. (Source: Journal of Plasti...
Source: Journal of Plastic, Reconstructive and Aesthetic Surgery - June 2, 2017 Category: Cosmetic Surgery Authors: Catriona Neville, Vanessa Venables, Margaret Aslet, Charles Nduka, Ruben Kannan Source Type: research

Botulinum Toxin for the Treatment of Gummv Smile.
CONCLUSION: Botox type I is an effective conservative technique to improve gummy smile caused by muscular hyperfunction. CLINICAL SIGNIFICANCE: Patients' retention highly indicated that they were satisfied with the provided treatment by Botox injections. Improving the quality of life with least painful experience and immediate results was the major advantage for Botox type I. PMID: 28621277 [PubMed - in process] (Source: J Contemp Dent Pract)
Source: J Contemp Dent Pract - June 1, 2017 Category: Dentistry Authors: Al-Fouzan AF, Mokeem LS, Al-Saqat RT, Alfalah MA, Alharbi MA, Al-Samary AE Tags: J Contemp Dent Pract Source Type: research

Botulinum toxin: State of the art
ABSTRACT Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions. In addition to onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin...
Source: Movement Disorders - June 1, 2017 Category: Neurology Authors: Joseph Jankovic Tags: Review Source Type: research

Predictive factors associated with eyebrow lifting by botulinum toxin type A
Background: Eyebrow lifting improves the appearance of eyelid hooding and widens the eyes. Botulinum toxin A(BTx-A) injection to lift the eyebrows has been used with highly satisfaction but variable outcomes. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - May 31, 2017 Category: Dermatology Source Type: research

OnabotulinumtoxinA (BOTOX) displays superior activity to incobotulinumtoxinA drug product (Xeomin) in multiple in vitro and in vivo assays
This study was to assess in vivo and in vitro activity of 50U, 100U and 200U vials of IncoA in relation to 100U OnaA product. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - May 31, 2017 Category: Dermatology Source Type: research

Synergistic effect of combination deoxycholic acid and botulinum toxin for the treatment of submental fullness
This report details a case of submental fullness successfully treated with a single session of combination deoxycholic acid and botulinum toxin type A (BoNTA). A 46-year-old otherwise healthy woman presented with concern regarding submental fullness. She had a history of prior treatment of upper face rhytides with BoNTA, but no history of cosmetic intervention for the neck. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - May 31, 2017 Category: Dermatology Source Type: research

Detection of Botulinum Toxin Muscle Effect in Humans Using Magnetic Resonance Imaging: A Qualitative Case Series
Conclusions This descriptive case series is among the first attempts to quantify BTME within human muscle. Our findings are preliminary and are limited by a few inconsistencies. However, we conclude that use of magnetic resonance imaging to detect the volume of BTME is feasible and may assist researchers in modeling the spread and diffusion of BT within human muscle. Level of Evidence To be determined. (Source: PMandR)
Source: PMandR - May 31, 2017 Category: Rehabilitation Source Type: research

Goals Set by Patients Using the ICF Model before Receiving Botulinum Injections and Their Relation to Spasticity Distribution.
Conclusion: Our results show that patients receiving BoNTA treatment set a higher percentage of activity and participation goals than body functions and structures goals. Goal classification was not affected by type of spasticity distribution or type of UMN disorder. PMID: 28539691 [PubMed - in process] (Source: Physiotherapy Canada)
Source: Physiotherapy Canada - May 27, 2017 Category: Physiotherapy Authors: Choi K, Peters J, Tri A, Chapman E, Sasaki A, Ismail F, Boulias C, Reid S, Phadke CP Tags: Physiother Can Source Type: research

Preoperative preparation of «loss of domain» hernia. Progressive pneumoperitoneum and botulinum toxin type A.
Preoperative preparation of «loss of domain» hernia. Progressive pneumoperitoneum and botulinum toxin type A. Cir Esp. 2017 May 26;: Authors: Bueno-Lledó J, Torregrosa Gallud A, Jiménez Rosellón R, Carbonell Tatay F, García Pastor P, Bonafé Diana S, Iserte Hernández J Abstract Preoperative progressive pneumoperitoneum and botulinum toxin type A are useful tools in the preparation of patients with loss of domain hernias. Both procedures are complementary in the surgical repair, especially with the use of prosthetic techniques without tension, that a...
Source: Cirugia eEspanola - May 26, 2017 Category: Surgery Authors: Bueno-Lledó J, Torregrosa Gallud A, Jiménez Rosellón R, Carbonell Tatay F, García Pastor P, Bonafé Diana S, Iserte Hernández J Tags: Cir Esp Source Type: research

Botulinum toxin a for adolescents with persisting post-concussion headaches: a case series
Conclusions Based on this small clinical sample of adolescents with severe persistent post-concussion headaches, Botox appears to be a well-tolerated and safe treatment option. Prospective, RCT studies are required to confirm this preliminary clinical impression. Competing interests None. (Source: British Journal of Sports Medicine)
Source: British Journal of Sports Medicine - May 25, 2017 Category: Sports Medicine Authors: Purtzki, J., Chan, C. Tags: Abstracts Source Type: research

Long-term anti-itch effect of botulinum neurotoxin A is associated with downregulation of TRPV1 and TRPA1 in the dorsal root ganglia in mice
Itch is a common symptom in patients with skin and systemic diseases, but the effective treatment is limited. Here, we evaluated the anti-itch effects of the botulinum toxin type A (BoNT/A) using acute and chronic dry skin itch mouse models, which were induced by compound 48/80, chloroquine, and a mixture of acetone–diethylether–water treatment, respectively. Pretreatment of intradermal BoNT/A exerted long-term inhibitory effects on compound 48/80-induced and chloroquine-induced acute itch on days 1, 3, 7, and 14, but not on day 21, in mice. Furthermore, a single injection of BoNT/A reduced the expression of th...
Source: NeuroReport - May 20, 2017 Category: Neurology Tags: Cellular, Molecular and Developmental Neuroscience Source Type: research

The diagnosis and management of a vertebral artery loop causing cervical radiculopathy
ConclusionVertebral artery loop formations are a rare but potential cause for cervical radiculopathy. In two cases, the loop formations were not radiographically reported on MRI, thus clinicians should be aware of this as a differential diagnosis in the management of cervical radiculopathy. The presented surgical approach may be useful in managing future cases of vertebral artery loop formation causing cervical radiculopathy resistant to conservative measures. (Source: European Spine Journal)
Source: European Spine Journal - May 20, 2017 Category: Orthopaedics Source Type: research

Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
ConclusionsElderly and/or multiparous women are at increased risk of urinary retention after intravesical 100-U Botox injections. The risk of new onset urine retention in our study has completely disappeared 2  weeks after Botox injections. Based on our results of the way in which the PVRs have changed over time, we can conclude that OAB patients should be optimally assessed during the first 2 weeks after Botox injections. (Source: International Urogynecology Journal)
Source: International Urogynecology Journal - May 19, 2017 Category: OBGYN Source Type: research

Employer Reactions to Adductor Spasmodic Dysphonia: Exploring the Influence of Symptom Severity and Disclosure of Diagnosis During a Simulated Telephone Interview
Conclusions Symptom severity in ADSD influences employer perceptions during the phone interview process. Incorrect assumptions may be made about applicants with severe symptoms, and apparentness of symptoms influences whether or not disclosure is recommended. Results have implications for counseling individuals with ADSD who are navigating the job interview process. (Source: American Journal of Speech-Language Pathology)
Source: American Journal of Speech-Language Pathology - May 17, 2017 Category: Speech-Language Pathology Source Type: research

[Myths and evidence on the use of botulinum toxin: spasticity in adults and in children with cerebral palsy].
CONCLUSIONS: This review is a tool for continuous training for neurologist and rehabilitation specialist and residents of both specialties, about different specific areas of the management of BTA. PMID: 28497442 [PubMed - in process] (Source: Revista de Neurologia)
Source: Revista de Neurologia - May 14, 2017 Category: Neurology Authors: Martinez-Castrillo JC, Pena-Segura JL, Sanz-Cartagena P, Alonso-Curco X, Arbelo-Gonzalez JM, Arriola-Pereda G, Coll-Bosch MD, Conejero-Casares JA, Garcia-Ribes A, Jauma-Classen S, Pagonabarraga J, Vidal-Valls J, Garcia-Ruiz PJ Tags: Rev Neurol Source Type: research

The real-world efficacy of botulinum toxin type a (botox(R)) for the prophylaxis of headaches in adult patients with chronic migraine in australian clinical practice: a retrospective chart review
Conclusions In an Australian clinical practice review, almost three-quarters of CM patients obtained a meaningful reduction in headache days following two BOTOX treatments, fulfilling PBS continuation criterion. Additionally, the use of acute migraine medicines, including opioids, was reduced. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 8, 2017 Category: Neurosurgery Authors: Stark, C., Stark, R., Limberg, N., Andrews, C., Rodrigues, J., Cordato, D., Schwartz, R., Michelle, F. J., Jonathan, T. Tags: Abstracts Source Type: research

Outcomes of Botulinum Toxin Type A for equinovarus deformity in patients with CVA: A case series.
CONCLUSION: Although BTX-A injections improved spasticity, this improvement did not translate to gait outcomes. Addition of physical therapy interventions appeared to improve gait outcomes in this case series. We suggest future randomized control studies to compare effects of physical therapy alone to BTX-A combined with physical therapy on gait outcomes. PMID: 28481738 [PubMed - as supplied by publisher] (Source: Physiotherapy Theory and Practice)
Source: Physiotherapy Theory and Practice - May 8, 2017 Category: Physiotherapy Authors: Karakkattil P, Trudelle-Jackson E, Brown HH, Hammontree P, Okolo M Tags: Physiother Theory Pract Source Type: research

Employer Reactions to Adductor Spasmodic Dysphonia: Exploring the Influence of Symptom Severity and Disclosure of Diagnosis During a Simulated Telephone Interview.
Conclusions: Symptom severity in ADSD influences employer perceptions during the phone interview process. Incorrect assumptions may be made about applicants with severe symptoms, and apparentness of symptoms influences whether or not disclosure is recommended. Results have implications for counseling individuals with ADSD who are navigating the job interview process. PMID: 28492935 [PubMed - as supplied by publisher] (Source: American Journal of Speech-Language Pathology)
Source: American Journal of Speech-Language Pathology - May 8, 2017 Category: Speech-Language Pathology Authors: Isetti DD, Baylor CR, Burns MI, Eadie TL Tags: Am J Speech Lang Pathol Source Type: research

Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain.
Abstract Arthritis pain affects people's long-term health, and recent studies have demonstrated that transient receptor potential vanilloid type 1 (TRPV1) plays a crucial role in arthritis pain. In addition, Pre-clinical evidence indicated that botulinum toxin type A (BoNT/A) has antinociceptive effect. The present study investigated the causality between the antinociceptive effects of BoNT/A and the expression of TRPV1 in dorsal root ganglion (DRG) in rats with adjuvant-arthritis pain. The results showed that BoNT/A significantly reduced adjuvant-arthritis nociceptive behaviors in a dose-dependent manner. Further...
Source: Toxicon - May 3, 2017 Category: Toxicology Authors: Fan C, Chu X, Wang L, Shi H, Li T Tags: Toxicon Source Type: research

Anatomical Regional Targeted (ART) BOTOX Injection Technique: A Novel Paradigm for Migraines and Chronic Headaches: Erratum
Source: Plastic and Reconstructive Surgery Global Open - May 1, 2017 Category: Cosmetic Surgery Tags: Erratum Source Type: research

Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke
Current guidelines suggested a dosage up to 600units (U) of botulinum toxin type A (BoNT-A) (onabotulinumtoxinA or incobotulinumtoxinA) in reducing spastic hypertonia with low prevalence of complications, although a growing body of evidence showed efficacy with the use of high doses (>800U). The available evidence mainly referred to a single set of injections evaluating the efficacy and safety of the neurotoxin 30days after the treatment. In a prospective, non-randomized, open-label study, we studied the safety of repeated higher doses of incobotulinumtoxinA in post-stroke upper and lower limb spasticity. (Source: Journ...
Source: Journal of the Neurological Sciences - May 1, 2017 Category: Neurology Authors: Andrea Santamato, Francesco Panza, Domenico Intiso, Alessio Baricich, Alessandro Picelli, Nicola Smania, Francesca Fortunato, Davide Seripa, Pietro Fiore, Maurizio Ranieri Source Type: research

1144 Poem With Massive Fibrosis Throughout the Submucosal Tunnel
A 17 year-old woman with 12 months history of dysphagia and regurgitation was firstly diagnosed of Bulimia Nervosa. After upper endoscopy, barium esophagram and High Resolution Manometry (HRM), slightly sigmoid Type II Achalasia was discovered. HRM features included altered lower esophageal sphincter (LES) relaxation with 43 mmHg 4sIRP and no normal peristalsis with long lasting and intense pan esophageal pressurizations. Eckardt basal score 10 and Dysphagia Score 4. EUS-guided BoTox injection in LES was performed. (Source: Gastrointestinal Endoscopy)
Source: Gastrointestinal Endoscopy - April 28, 2017 Category: Gastroenterology Authors: Eduardo Albeniz, Marta G ómez, Fermín Estremera, Maria Rullan, Areste Irene, Rosa Iglesias, Juan J. Vila Tags: Oral abstract Source Type: research

Different Glabellar Contraction Patterns in Chinese and Efficacy of Botulinum Toxin Type A for Treating Glabellar Lines: A Pilot Study
CONCLUSION: The classification of 5 glabellar patterns is compatible for the Chinese population despite different proportions. The dosage of BoNTA should be less than 20 U during treatment in China with lowered incidence of complications. (Source: Dermatologic Surgery)
Source: Dermatologic Surgery - April 28, 2017 Category: Dermatology Tags: Original Article Source Type: research

Comparison of the Expression Changes after Botulinum Toxin Type A and Minocycline Administration in Lipopolysaccharide-Stimulated Rat Microglial and Astroglial Cultures
Anna Piotrowska, Katarzyna Popiolek-Barczyk, Flaminia Pavone, Joanna Mika (Source: Frontiers in cellular and infection microbiology)
Source: Frontiers in cellular and infection microbiology - April 26, 2017 Category: Microbiology Source Type: research

Evaluation of the protective effect of Botulinum toxin type A injection on otitis media with effusion().
CONCLUSIONS: Botulinum toxin type A blocked the secretion of glands in the middle ear and showed no effect to prevent the formation of serous otitis. In addition, it was found out that Botulinum toxin did not lead to any morphological change in the cochlea. PMID: 28434389 [PubMed - as supplied by publisher] (Source: Acta Oto-Laryngologica)
Source: Acta Oto-Laryngologica - April 22, 2017 Category: ENT & OMF Authors: Çalım ÖF, Yıldırım YS, Doğan R, Tuğrul S, Gedik Ö, Özturan O Tags: Acta Otolaryngol Source Type: research

Two cases of acute allergic reaction following injection of generic, government-provided botulinum toxin a (ggp-bta) for hemifacial spasm and blepharospasm (p3.028)
Conclusions:We reported two cases of facial angioedema following injection of GGP-BTA, with resolution after adequate systemic treatment with anti-allergic medications.Disclosure: Dr. Parolin has nothing to disclose. Dr. Germiniani has nothing to disclose. Dr. Teive has nothing to disclose. Dr. Scola has nothing to disclose. Dr. Borges has nothing to disclose. Dr. Parolin has nothing to disclose. Dr. Parolin has nothing to disclose. Dr. Parolin has nothing to disclose. Dr. Parolin has nothing to disclose. Dr. Parolin has nothing to disclose. Dr. Parolin has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Parolin, L., Germiniani, F., Teive, H. A., Scola, R., Borges, C., canever, m., scavasine, v., ribas, g., Miksza Tholken, K. F., Brenner, F. M., Serafini, S. Z. Tags: Movement Disorders: Dystonia and Neurotoxin Therapies Source Type: research

Improvement of Dystonia Management by Specific Training of General Neurologist and Family Doctors (P3.018)
Conclusions:Collaboration in specific training could represent the basis for improving all aspects of dystonia management especially diagnosis and therapy.Study Supported by: Croatian Science FundationDisclosure: Dr. Relja has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Relja, M. Tags: Movement Disorders: Dystonia and Neurotoxin Therapies Source Type: research

Duration of Botox effects in Neuromuscular junction using single fiber EMG (P2.138)
Conclusions:Effect of Botox last up to 9 months after injection using single fiber EMG. In case of a subject with ptosis and history of Botox injection, we recommend a baseline single fiber EMG and then follow ups 6, 9 and 12 months after injection. These data would decrease the number of false positive ocular mysthenia.Study Supported by: NADisclosure: Dr. Bayat has nothing to disclose. Dr. Russo has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Bayat, E., Russo, M. Tags: Myopathies & amp;amp; Myasthenia Gravis II Source Type: research

What kind of treatment do patients really want for headache? (P1.186)
Conclusions:The majority of patients with headache are offered only medication treatment options, yet the preference of a majority of patients is an integrative approach that includes a combination of medication and non-medication treatments. Only a small minority of patients prefers medication only. It is important to open a conversation regarding patient preferences when partnering with patients to improve adherence to a treatment plan.Disclosure: Dr. Murinova has nothing to disclose. Dr. Schorn has nothing to disclose. Dr. Krashin has nothing to disclose. Dr. Chan-Goh has nothing to disclose. (Source: Neurology)
Source: Neurology - April 17, 2017 Category: Neurology Authors: Murinova, N., Schorn, M., Krashin, D., Chan-Goh, S. M. Tags: Headache: Epidemiology and Disease Characteristics Source Type: research

Botulinum toxin type A in the treatment of facial myotonia in SChwartz ‐Jampel syndrome
(Source: Muscle and Nerve)
Source: Muscle and Nerve - April 8, 2017 Category: Internal Medicine Authors: Igor D órea Bandeira, João Gabriel Jagersbacher, Thiago Lima Barretto, Camilo Vieira Santos, Rita Lucena Tags: Noteworthy Cases Source Type: research

[Management of upper eyelid retraction associated with dysthyroid orbitopathy during the acute inflammatory phase with botulinum toxin type A].
CONCLUSION: Transconjunctival BTX-A application is safe and effective for the treatment of eyelid retraction in dysthyroid orbitopathy. No difference was found between doses. No severe side effects were reported. PMID: 28336282 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - March 27, 2017 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: A case series.
Authors: Baker JS, Nolan PJ Abstract BACKGROUND: The aim of this study is to evaluate the effectiveness of botulinum toxin type A (BTX-A) for the treatment of chronic masticatory myofascial pain (MMP) over 12 months and to test a standardized protocol. METHODS: This is a prospective case series of consecutive adult patients with chronic MMP treated with injection of BTX-A into the bilateral temporalis and masseter muscles. The authors used the same anatomic landmarks and dosage and followed each patient for 12 months. The primary outcome variables were reduction in pain measured with visual analog scale (V...
Source: Journal of the American Dental Association - March 23, 2017 Category: Dentistry Tags: J Am Dent Assoc Source Type: research

The Effect of Botulinum Toxin Type A on Expression Profiling of Long Noncoding RNAs in Human Dermal Fibroblasts.
Conclusion. The expression profiling of lncRNAs was visibly changed in BoNTA treated HDFs. Further studies should focus on several lncRNAs to investigate their functions in BoNTA treated HDFs and the underlying mechanisms. PMID: 28265570 [PubMed - in process] (Source: Biomed Res)
Source: Biomed Res - March 8, 2017 Category: Research Authors: Miao YY, Liu J, Zhu J, Tao YL, Zhang JA, Luo D, Zhou BR Tags: Biomed Res Int Source Type: research

Targeted Peripheral Nerve-directed Onabotulinumtoxin A Injection for Effective Long-term Therapy for Migraine Headache
Source: Plastic and Reconstructive Surgery Global Open - March 1, 2017 Category: Cosmetic Surgery Tags: Original Article Source Type: research

Head Drop after Botox: Electrodiagnostic Evaluation of Iatrogenic Botulinum Toxicity
Systemic weakness following botulinum neurotoxin injection is rare. Life-threatening cases of iatrogenic botulism have been reported following lethal doses of unlicensed preparations. In adults, iatrogenic botulism has been reported in hereditary spastic paraparesis, limb dystonia, hemiparesis, and even following detrusor injection for neurogenic bladder. In the majority of reported cases, clinical criteria have established the diagnosis (Bakheit et al., 1997, Bhatia et al., 1999, Coban et al., 2010, [1]). (Source: Clinical Neurology and Neurosurgery)
Source: Clinical Neurology and Neurosurgery - February 26, 2017 Category: Neurosurgery Authors: Eliza Szuch, James B. Caress, Bandhu Paudyal, Allison Brashear, Michael S. Cartwright, Roy E. Strowd Source Type: research

Mandibular Rim Trilogy with Botulinum Toxin Injection: Reduction, Projection, and Lift
Facial plast Surg 2017; 33: 102-108 DOI: 10.1055/s-0037-1600525“Onabotulinum toxin A (Botox) revolution” has brought the fundamental change in the facial rejuvenation as well as the concept of microinjection. The aesthetic standard tends to be the “globalization”; however, Asians have different aesthetic cultures and unique facial features compared with Caucasians. A new rejuvenation concept is proposed during our practice; the Asian face should preserve the original facial identity during Botox treatments. The lower face is treated with botulinum toxin to achieve a harmonious facial profile. Twenty...
Source: Facial Plastic Surgery - February 22, 2017 Category: Cosmetic Surgery Authors: Zhou, Renpeng Pan, Benyun Wang, Chen Wang, Danru Tags: Rapid Communication Source Type: research

Facial Manifestations of Pachydermoperiostosis Treated with Botulinum Toxin Type-A: Report of 3 Cases.
Abstract is missing (Short communication). PMID: 28224169 [PubMed - as supplied by publisher] (Source: Acta Derm Venereol A...)
Source: Acta Derm Venereol A... - February 22, 2017 Category: Dermatology Authors: Wen X, Li Y, Hamblin MR, Jiang X Tags: Acta Derm Venereol Source Type: research

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated
Conclusion Treatment of HFS with BTX-A wa s effective, sustainable and safe and had minimal, well-tolerated side effects.RESUMO O espasmo hemifacial (EHF) é um distúrbio do movimento comum, caracterizado pela presença de contrações musculares tônicas ou clônicas dos músculos inervados pelo nervo facial. Objetivo Avaliar o efeito em longo prazo do uso da toxina botulínica tipo A (TXB) no tratamento do espasmo hemifacial (EHF). Métodos Foi realizada uma análise retrospectiva de pacientes do Ambulatório de Distúrbios do Movimento do depar...
Source: Arquivos de Neuro-Psiquiatria - February 21, 2017 Category: Neurology Source Type: research

Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats.
CONCLUSION: These results demonstrate that intra-articular injection of BoNT-A reduces the albumin-induced arthritis persistent hypernociception in TMJ of rats by peripheral inhibition of neuropeptides release. PMID: 28209481 [PubMed - as supplied by publisher] (Source: Toxicon)
Source: Toxicon - February 13, 2017 Category: Toxicology Authors: Manuel Muñoz Lora VR, Trindade Clemente-Napimoga J, Ballassini Abdalla H, Gomes Macedo C, de la Torre Canales G, Rizzatti Barbosa CM Tags: Toxicon Source Type: research

Botulinum toxin type A (BTX ‐A) in the treatment of facial myotonia in Schwartz‐Jampel Syndrome
(Source: Muscle and Nerve)
Source: Muscle and Nerve - February 10, 2017 Category: Internal Medicine Authors: Igor D órea Bandeira, João Gabriel Jagersbacher, Thiago Lima Barretto, Camilo Vieira Santos, Rita Lucena Tags: Noteworthy Case Source Type: research

Effect of BTXA on Inhibiting Hypertrophic Scar Formation in a Rabbit Ear Model
AbstractBackgroundHypertrophic scar (HS) is a refractory skin disease caused by major physical damage or other inflammation. Some reports found that botulinum toxin type A (BTXA) could be an alternative treatment of the HS. Therefore, the authors studied the effects of BTXA on the treatment of HS and the dose response of BTXA.MethodsHypertrophic scars were harvested from the ears of 18 young adult New Zealand big-eared rabbits and treated with BTXA or triamcinolone acetonide (TAC) in vivo experiment. The hypertrophic index (HI) was measured by histological examination. Collagen fibrils were checked by sirius red straining,...
Source: Aesthetic Plastic Surgery - February 8, 2017 Category: Cosmetic Surgery Source Type: research

Assessing the immediate impact of botulinum toxin injection on impedance of spastic muscle
Since the 1980s, Botulinum toxin type A (BoNT-A) has been widely used in the management of spasticity caused by stroke, spinal cord injury, or cerebral palsy [1 –5]. The underlying mechanisms of BoNT-A is that it can effectively block the release of acetylcholine from the nerve endings, thus producing a progressive paralysis of the muscle [1,6]. Subsequent to the intramuscular BoNT-A injection, alterations in the physiological and mechanical properties of muscle have been reported in histological, mechanical, and medical imaging studies [7–11]. (Source: Medical Engineering and Physics)
Source: Medical Engineering and Physics - February 4, 2017 Category: Biomedical Engineering Authors: Xiaoyan Li, Henry Shin, Le Li, Elaine Magat, Sheng Li, Ping Zhou Tags: Technical note Source Type: research

Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis
Introduction Multiple sclerosis (MS) is a severe debilitating disease that affects patients' quality of life. Up to 90% of patients with MS will develop lower urinary tract dysfunction within the first 18 years of the disease. If oral pharmacotherapy with anticholinergics, behavioural modifications and pelvic floor physical therapy are unsuccessful, intradetrusor injection of botulinum toxin-A (OnaBotA; Botox Allergan, Dublin, Ireland) is a highly effective option for these patients. The local effects of OnaBotA are well understood, but not much is known of its afferent/sensory effects while treating the end organ. Ou...
Source: BMJ Open - February 3, 2017 Category: Journals (General) Authors: Elizondo, R. A., Karmonik, C., Boone, T. B., Khavari, R. Tags: Open access, Neurology, Radiology and imaging, Research methods, Urology, Obgyn Protocol Source Type: research

Anatomical relationships of the procerus with the nasal ala and the nasal muscles: transverse part of the nasalis and levator labii superioris alaeque nasi
ConclusionThis study has yielded crucial data for understanding the anatomical relationships and functions of the procerus in relation to the nose. They will be helpful when designing effective therapies involving botulinum toxin type A, performing various types of rhinoplasty and facial surgeries, and in electromyography analyses. (Source: Surgical and Radiologic Anatomy)
Source: Surgical and Radiologic Anatomy - January 28, 2017 Category: Anatomy Source Type: research

Topical Review: Potential Use of Botulinum Toxin in the Management of Painful Posttraumatic Trigeminal Neuropathy.
Authors: Moreau N, Dieb W, Descroix V, Svensson P, Ernberg M, Boucher Y Abstract Painful posttraumatic trigeminal neuropathy (PPTTN) is a chronic condition that is difficult to endure and has a poorly understood pathophysiology. Treatment options are limited and often unsatisfactory due to insufficient efficacy and significant adverse effects. Botulinum toxin type A (BTX-A), initially used in the management of pathologically sustained or twisting muscular contractions, has recently been advocated for treatment of neuropathic pain. Its action is not limited to the blockage of acetylcholine release at the neuromuscul...
Source: Journal of Orofacial Pain - January 25, 2017 Category: ENT & OMF Tags: J Oral Facial Pain Headache Source Type: research

Preoperative progressive pneumoperitoneum and botulinum toxin type A in patients with large incisional hernia
AbstractPurposeCombination of preoperative progressive pneumoperitoneum (PPP) and botulinum toxin type A (BT) has not been previously reported in the management of large incisional hernia (LIH).MethodsObservational study of 45 consecutive patients with LIH between June 2010 and July 2014. The diameters of the hernia sac, the volumes of the incisional hernia (VIH) and the abdominal cavity (VAC), and the VIH/VAC ratio were measured before and after PPP and BT using abdominal CT scan data. We indicated the combination of both techniques when the volume of the incisional hernia (VIH)/volume of the abdominal cavity (VAC) ratio ...
Source: Hernia - January 25, 2017 Category: Sports Medicine Source Type: research

Treatment of the first bite syndrome.
, Gómez J, Llorente JL Abstract First bite syndrome is a potential complication of surgery involving the infratemporal fossa, deep lobe of the parotid gland and parapharyngeal space. It is described as an acute and intense pain in the parotid region caused with the first bite of each meal. It is related to damage to sympathetic innervation of the parotid gland. Parasympathetic hyperactivation is believed to stimulate an exaggerated myoepithelial cell contraction causing pain. Usual analgesic treatments have poor results. Botulinum toxin type A causes parasympathetic nerve paralysis of the parotid gland and ...
Source: Acta Otorrinolaringologica Espanola - January 21, 2017 Category: ENT & OMF Authors: Costales-Marcos M, López Álvarez F, Fernández-Vañes L, Gómez J, Llorente JL Tags: Acta Otorrinolaringol Esp Source Type: research

Factors in the Efficacy, Safety, and Impact on Quality of Life for Treatment of Drooling with Botulinum Toxin Type A in Patients with Cerebral Palsy
Objective: To assess the efficacy and safety of botulinum toxin A (BoNT-A) injected in both submandibular and parotid versus only in parotid glands as a treatment for drooling in patients with spastic and dyskinetic cerebral palsy (CP), including an assessment of impact on quality of life (QoL) based on items from the International Classification of Functioning, Disability, and Health (ICF) core set. Design: Forty patients with CP 18 years or older (mean, 21.8 years) participated in a prospective, single-center, randomized controlled interventional study. All participants were classified as Gross Motor Function Classifica...
Source: American Journal of Physical Medicine and Rehabilitation - January 19, 2017 Category: Rehabilitation Tags: Original Research Articles Source Type: research